Ebola kills roughly 6 out of every 10 people it infects. A meta-analysis covering all 42 recorded outbreaks from 1976 to 2022 found a pooled case fatality rate of 60.6%, making it one of the deadliest infectious diseases known to medicine. That average, though, masks a wide range depending on the viral strain, the speed of medical care, and where the outbreak occurs.
Fatality Rates by Strain
There are four strains of Ebola virus that cause disease in humans, and they vary dramatically in lethality. The Zaire strain is the most dangerous, with a case fatality rate of 66.6%. It was responsible for the largest outbreak in history, the 2014-2016 epidemic in West Africa, which infected more than 28,600 people and killed 11,325. The Sudan strain kills about 48.5% of those infected, and the Bundibugyo strain around 32.8%.
The fourth strain, Taï Forest virus, has only ever caused a single confirmed human case, a researcher who became ill after performing a necropsy on a chimpanzee in Côte d’Ivoire in 1994. She survived, giving it a recorded fatality rate of 0%, though that number is essentially meaningless with a sample size of one.
Within any given strain, individual outbreaks have ranged from roughly 13% to over 90% fatality, depending largely on how quickly patients received care and how well-equipped the responding health system was.
How Ebola Kills
Ebola doesn’t kill through a single mechanism. It launches a cascading attack on the immune system, blood vessels, and major organs simultaneously.
The virus first targets immune cells called macrophages and dendritic cells, essentially hijacking the body’s first responders. This triggers a massive, uncontrolled release of inflammatory signals, sometimes called a cytokine storm. The flood of contradictory chemical signals damages immune cells, surrounding tissues, and the walls of blood vessels. As disease progresses, abnormal production of nitric oxide contributes to tissue damage, loss of vascular integrity, and eventually shock.
At the same time, Ebola actively suppresses the adaptive immune system. Infected immune cells lose their ability to activate T cells, which are critical for clearing the virus. In fatal cases, researchers have observed massive die-off of white blood cells in the bloodstream in the days immediately before death, leaving the body unable to mount a meaningful defense.
The virus also directly infects liver cells, lung tissue, kidney cells, and cells lining blood vessels. As these organs begin to fail, blood vessels become increasingly leaky, allowing fluid to seep into surrounding tissues. The lining of blood vessels becomes inflamed and procoagulant, meaning it promotes abnormal clotting, which paradoxically leads to both clotting problems and hemorrhage. This combination of organ failure, internal bleeding, and vascular collapse is what ultimately proves fatal.
How Early Treatment Changes Survival
The quality and timing of medical care has a dramatic effect on survival. During the 2014-2016 West African epidemic, mortality fell to less than 40% as outbreak responders improved case finding and patients presented earlier for treatment. Patients evacuated to hospitals in Europe and the United States, where they received aggressive supportive care including intravenous fluids and electrolyte management, saw an even larger benefit, with absolute mortality dropping by 20 to 30 percentage points compared to field conditions.
There is now also an approved treatment specifically for the Zaire strain. In clinical trials, patients receiving this monoclonal antibody therapy had a 28-day mortality rate of 34%, compared with 51% in the control group. That’s a meaningful improvement, though it still leaves Ebola with a fatality rate several times higher than most infectious diseases even with the best available treatment.
How Ebola Spreads
Ebola is not airborne. It spreads through direct contact with the blood, body fluids, or tissues of an infected person or animal. The incubation period ranges from 2 to 21 days, and crucially, people cannot transmit the virus before symptoms appear. Once symptomatic, a person remains infectious as long as the virus is detectable in their blood.
The virus is believed to originate in bats, though the exact natural reservoir has not been definitively confirmed. Research on a species of African fruit bat shows that Ebola can replicate in and transmit between these animals in ways consistent with a reservoir host. Spillover to humans likely occurs through contact with infected bats or other wildlife, particularly during activities like cave exploration or bushmeat hunting. Birthing seasons in bat colonies may drive seasonal peaks in spillover risk.
Vaccination Has Changed the Outlook
A vaccine targeting the Zaire strain showed 100% efficacy in a phase III trial during the Guinea outbreak, with none of the 2,119 vaccinated contacts developing disease. In real-world use during outbreaks in the Democratic Republic of Congo in 2018-2019, where over 200,000 people were vaccinated, effectiveness was estimated at 97.5%. This vaccine is now a core tool in outbreak response, used in a “ring vaccination” strategy where contacts of confirmed cases and their contacts are vaccinated to create a buffer zone around each case.
No equivalent vaccine exists yet for the Sudan or Bundibugyo strains, which means outbreaks caused by those viruses still rely entirely on isolation, contact tracing, and supportive care.
Life After Surviving Ebola
Surviving Ebola does not mean a full return to health. In studies of survivors from Sierra Leone, every single participant reported at least one lingering symptom, with a median of two and as many as five. The most common complaints were musculoskeletal pain (70% of survivors), headaches (48%), and eye problems (14%). Other reported symptoms include abdominal pain, vision loss, hearing loss, extreme fatigue, and psychological difficulties.
These symptoms, collectively known as Post-Ebola Syndrome, can persist for months or years. Data from earlier outbreaks found that a quarter of survivors were still seeking medical care a full year after their acute illness. Joint pain and eye inflammation have been documented across multiple outbreaks spanning decades, suggesting these are consistent features of recovery rather than isolated findings.